Overview
Enoxaparin Ledraxen® is a premium sterile anticoagulant solution manufactured by Venopharm. It contains Enoxaparin Sodium, a Low Molecular Weight Heparin (LMWH) widely used for the prevention and treatment of thromboembolic disorders. This 4.000 IE (40 mg) presentation is one of the most commonly prescribed dosages for thromboprophylaxis. It is suitable for both subcutaneous and intravenous administration and is supplied in a box of 10 ready-to-use pre-filled syringes, each equipped with an advanced safety system for maximum healthcare professional protection.

Key Features and Benefits

• Standard Prophylactic Dose: Each pre-filled syringe delivers exactly 4.000 IE Anti-Xa (40 mg) of Enoxaparin Sodium in a 0.4 ml solution, representing the standard dose for thromboprophylaxis in moderate-risk patients.
• Dual Route of Administration: Formulated for flexible use, indicated for both subcutaneous injection (routine prophylaxis) and intravenous use (for specific procedures including extracorporeal applications).
• Extracorporeal Application: Specifically indicated for use in extracorporeal circuits, particularly the dialysis circuit, to prevent clotting during hemodialysis sessions.
• Ready-to-Use Precision: The pre-filled format eliminates manual drawing errors, ensures dosing accuracy, and saves valuable clinical time in busy hospital environments.
• Integrated Safety System: Each syringe features a passive safety mechanism that activates immediately after injection, shielding the needle to significantly reduce the risk of accidental needle-stick injuries.
• Premium Pharmaceutical Quality: Manufactured by Venopharm, ensuring strict adherence to international pharmaceutical quality standards.

Indications and Usage
Enoxaparin Ledraxen® (4.000 IE) is primarily indicated for:

• Thromboprophylaxis in Surgery: Prevention of deep vein thrombosis (DVT) in patients undergoing moderate-risk surgical procedures.
• Thromboprophylaxis in Medical Patients: Prevention of venous thromboembolism in acutely ill medical patients with reduced mobility.
• Extracorporeal Circulation: Prevention of clot formation in the dialysis circuit during hemodialysis procedures.
• Initial Phase of DVT Treatment: Used as part of the therapeutic regimen for established DVT, with or without pulmonary embolism (dosing dependent on patient weight and clinical judgment).

Important Safety Information
This is a prescription medication intended for hospital or specialized clinical use only. It must be administered under the supervision of a qualified healthcare professional.

• Monitoring: Patients should be monitored for signs of bleeding or unusual bruising. Platelet counts should be monitored regularly due to risk of heparin-induced thrombocytopenia (HIT).
• Contraindications: Do not use in patients with active major bleeding, history of HIT, hypersensitivity to Enoxaparin or heparin derivatives, or active peptic ulcer disease.
• Renal Impairment: Dose adjustment may be required in patients with severe renal impairment.
• Storage: Store below 25°C. Do not freeze. Keep out of reach of children.

Product Specifications

• Active Ingredient: Enoxaparin Sodium
• Strength: 4.000 IE Anti-Xa (equivalent to 40 mg)
• Volume: 0.4 ml
• Route of Administration: Subcutaneous or Intravenous (Extracorporeal)
• Format: 10 Pre-filled syringes with Integrated Safety System
• Manufacturer: Venopharm

Disclaimer: This description is for informational purposes only and does not constitute medical advice. Always consult the official product leaflet and a qualified healthcare professional for complete prescribing information, contraindications, and proper administration guidelines.